Aspira Women's Health
- Country
- ๐บ๐ธUnited States
- Ownership
- -
- Employees
- 64
- Market Cap
- -
- Introduction
Aspira Women's Health, Inc. engages in the provision of bio-analytic and diagnostic services. Its product, OVA1, is a serum test for identifying women of having malignant ovarian tumor. Its bio-analytical solutions helps physicians diagnose, treat, and improve gynecologic health outcomes for women. The company was founded on December 9, 1993 and is headquartered in Austin, TX.
Deep Neural Network Stratification for Use Detecting Endometriosis in Women Affected by Chronic Pelvic Pain (EndoCheck)
- Conditions
- Endometriosis
- First Posted Date
- 2022-02-18
- Last Posted Date
- 2025-01-28
- Lead Sponsor
- Aspira Women's Health
- Target Recruit Count
- 1200
- Registration Number
- NCT05245695
- Locations
- ๐บ๐ธ
Cindy Basinski, MD, Newburg, Indiana, United States
๐บ๐ธNew Horizons Clinical Trials, Chandler, Arizona, United States
๐บ๐ธArizona Gynecology Consultants, Mesa, Arizona, United States
Multifactorial Risk Assessment for Breast & Ovarian Cancer Risk Detection
- Conditions
- Hereditary Breast and Ovarian CancerAdnexal MassGermline BRCA1 Gene MutationGermline BRCA2 Gene Mutation
- Interventions
- Other: OVA360
- First Posted Date
- 2020-12-16
- Last Posted Date
- 2023-12-26
- Lead Sponsor
- Aspira Women's Health
- Target Recruit Count
- 215
- Registration Number
- NCT04668521
- Locations
- ๐บ๐ธ
Silvana Franco, Austin, Texas, United States
A Multivariate Index Assay for Ovarian Cancer Risk Assessment in Women With Adnexal Mass and High-Risk Germline Variants
- Conditions
- Adnexal Mass
- Interventions
- Device: OVAnex
- First Posted Date
- 2020-07-27
- Last Posted Date
- 2023-12-26
- Lead Sponsor
- Aspira Women's Health
- Target Recruit Count
- 721
- Registration Number
- NCT04487405
- Locations
- ๐บ๐ธ
Northwell Health, New Hyde Park, New York, United States
๐บ๐ธAltus Research, Lake Worth, Florida, United States
๐บ๐ธWomen's Health Arizona, Chandler, Arizona, United States